Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Zepbound (Tirzepatide) Dosage Chart: 2.5 to 15 mg Guide
guidesComplete Zepbound (tirzepatide) dosage chart for weight management. Covers the full 2.5 mg to 15 mg titration schedule, SURMOUNT-1 weight loss by dose, KwikPen guide, missed-dose rules, and a Zepbound vs Wegovy comparison.
Tirzepatide Muscle Loss: What the SURMOUNT-1 DXA Data Shows
articleTirzepatide does not selectively break down muscle. In the SURMOUNT-1 DXA substudy the fat-to-lean split of weight lost matched the placebo arm, the most defensible finding in tirzepatide's body composition literature.
Zepbound Weight Loss Results: SURMOUNT-1 Dose-Stratified Data
articleThe dose-stratified Zepbound weight loss results from SURMOUNT-1 (5mg, 10mg, 15mg arms) with per-dose responder rates, plus SURMOUNT-2 (T2D), SURMOUNT-4 (maintenance), and SURMOUNT-5 (vs Wegovy) context. Brand-specific Zepbound evidence, FDA-label population.